Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Peripheral Nervous System Diseases 5Lymphoma 5Head and Neck Neoplasms 4Breast Neoplasms 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Stomatitis 2Stomach Neoplasms 2Sarcoma 2Pain 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Malnutrition 2Wilms Tumor 1Vaso-Occlusive Crises 1Squamous Cell Carcinoma of Head and Neck 1Sarcopenia 1Recurrence 1Radiation Injuries 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Oral Complications 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Malignant mesenchymal tumor 1

Interventions

Cyclophosphamide 193fludarabine phosphate 123Peripheral Blood Stem Cell Transplantation 107Etoposide 106Mycophenolic Acid 95Filgrastim 92Doxorubicin 85Whole-Body Irradiation 84Tacrolimus 81Brentuximab Vedotin 80Melphalan 78Busulfan 75Radiotherapy 74fludarabine 68Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 44pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Glutamine × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡